Business Trends– category –
-
Graphenea Unveils New Wafer-Scale Graphene Production Facility in Europe, Accelerating Semiconductor and Electronics Integration
Graphenea Press Release Europe Overview Graphenea, a leading graphene producer, has announced a new wafer-scale graphene production facility in Europe. This facility is poised to significantly boost the supply of high-quality graphene, a... -
Samsung Display Commits Massive Investment to Next-Gen QD-OLED Production, Targeting 2027 Market Leadership
Display Tech News South Korea Overview Samsung Display has announced a significant strategic investment to expand its next-generation Quantum Dot Organic Light Emitting Diode (QD-OLED) panel production capabilities, aiming for dominant m... -
Nanoparticle Therapy: Revolutionizing Drug Delivery for Enhanced Efficacy and Safety
Acibadem Hospitals Group Turkey Overview Nanoparticle therapy is a transformative platform technology that fundamentally enhances drug delivery across medical applications. By improving drug solubility, extending circulation time, and en... -
Gold Nanoparticles Revolutionize Prostate Cancer Treatment: Integrating Targeted Drug Delivery, Photothermal Therapy, and Multimodal Imaging
MDPI Switzerland Overview Gold nanoparticles (AuNPs) are emerging as promising multifunctional nanoplatforms for prostate cancer treatment, leveraging their tunable size, shape, surface plasmon resonance (SPR) properties, and high surfac... -
Nanoparticles Show Promise for Targeted Drug Delivery in Heart Failure: Applications for Fibrosis, Inflammation, and Gene Therapies
Circulation (AHA Journals) USA Overview Nanoparticle-based approaches are emerging as promising strategies to enhance targeted drug delivery for heart failure, addressing key pathophysiological areas such as TGF-β-mediated fibrosis, IL-1... -
FDA Releases Draft GDUFA/PDUFA Reauthorization Letters, Committing to Strengthen Cell and Gene Therapy Program and Leverage Real-World Evidence
Holland & Knight USA Overview The U.S. FDA has released draft commitment letters for the reauthorization of the Generic Drug User Fee Amendments (GDUFA) and Prescription Drug User Fee Act (PDUFA). These letters include the FDA's commitme... -
NurExone Accelerates U.S. Market Entry with GMP Exosome Manufacturing Partnership with Made Scientific, Targeting First Batch by H1 2027
BioPharma BoardRoom USA Overview Exo-Top Inc., a U.S. subsidiary of NurExone Biologic Inc., has signed an MOU with Made Scientific, Inc. for a GMP exosome manufacturing partnership in the U.S. This strategic alliance aims to accelerate N... -
FDA Finalizes Q&A Guidance on Cell and Gene Therapy Product Development, Clarifying Regulatory Review, CMC, and Safety Monitoring
RAPS (Regulatory Affairs Professionals Society) USA Overview The U.S. FDA has released final FAQ guidance on developing cell and gene therapy (CGT) products, providing practical answers to common regulatory questions spanning regulatory ... -
Xellsmart Secures FDA Fast Track Designation for Parkinson’s iPSC-Derived Cell Therapy, Accelerating CNS Pipeline
Longevity.Technology UK Overview Xellsmart announced its allogeneic, off-the-shelf iPSC-derived cell therapy for Parkinson's disease has received FDA Fast Track designation, expected to accelerate its development program. Specializing in... -
BlueRock Therapeutics Advances iPSC-Derived Dopamine Neuron Therapy bemdaneprocel to Phase 3 for Parkinson’s, Demonstrating Significant Motor Improvement in Early Data
RegenMed Review USA Overview BlueRock Therapeutics' iPSC-derived dopamine neuron therapy, bemdaneprocel, is progressing to a Phase 3 trial (exPDite-2) for Parkinson's disease. Earlier 36-month Phase 1 data showed clinically meaningful im...
